



Amlodipine and Olmesartan Medoxomil Tablets

Type of Posting	Revision Bulletin
Posting Date	30-Jan-2026
Official Date	1-Feb-2026
Expert Committee	Small Molecules

In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 2 Expert Committee has revised the Amlodipine and Olmesartan Medoxomil Tablets monograph. The purpose of this revision is to add *Dissolution Test 6* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s). The revision also necessitates a change in the table numbering in the test for *Organic Impurities*.

- *Dissolution Test 6* was validated using the Acquity UPLC HSS T3 brand of column with L1 packing. The typical retention times for amlodipine, olmesartan, and olmesartan medoxomil are 4.55, 1.30, and 6.55 min, respectively.

The Amlodipine and Olmesartan Medoxomil Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Jasmine Lawrence, Scientist IV (301-230-6363 or jasmine.lawrence@usp.org).